Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05065736 · ClinicalTrials.gov registry record · Early Phase 1
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
A Early Phase 1 study of Metastatic Cancer and Carcinoma, sponsored by Roberto Vargas.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT05065736: Recruiting Early Phase 1 study of Metastatic Cancer and Carcinoma, sponsored by Roberto Vargas.
NCT05065736 is a Early Phase 1 study of Metastatic Cancer and Carcinoma that is actively recruiting participants, run by Roberto Vargas. The registered enrollment target is 4 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05065736, a Early Phase 1 study of Metastatic Cancer and Carcinoma, is actively recruiting participants, sponsored by Roberto Vargas.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate whether a new type of imaging study, called 18F-Clofarabine (CFA) PET/CT, can be used to image cancer pyrimidine metabolism in participants. PET (positron emission tomography) imaging is a way of looking at cancers that can reveal cancer metabolism. Presently, however, there are no imaging agents in routine use to look at an aspect of cancer metabolism (pyrimidine metabolism) that dictates whether certain cancer drugs, e.g., gemcitabine, are likely to be taken into the cancer cells. This clinical trial will be testing whether 18F-Clofarabine (CFA) could be an imaging agent to measure this aspect of cancer metabolism.
Primary Outcome
Establish the image-based biodistribution of CFA, a new tracer for imaging DCK enzyme activity. DCK converts the inactive prodrug clofarabine into its active form. Thus, the degree of DCK expression in normal and abnormal tissues may predict drug effects and effectiveness. The uptake of the radiotracer (SUVs) will be measured quantitatively from PET images taken at 60 min post-injection of \[18F\]CFA.
Conditions Studied
Interventions
- DRUG 18F-Clofarabine
Study Locations (1)
Ohio
- Cleveland Clinic, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-03-06 |
| Est. Completion | 2026-06 |
| Phase | Early Phase 1 |
What NCT05065736 shows while recruiting
NCT05065736 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which 18F-Clofarabine is the first listed.
NCT05065736 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05065736 about?
NCT05065736 is a clinical study titled "Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer". The purpose of this study is to evaluate whether a new type of imaging study, called 18F-Clofarabine (CFA) PET/CT, can be used to image cancer pyrimidine metabolism in participants. PET (positron emission tomography) imaging is a way of looking at cancers that can reveal cancer metabolism. Presentl...
What is the current status of trial NCT05065736?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2023-03-06. Estimated completion is 2026-06.
What conditions does trial NCT05065736 study?
This clinical trial studies the following conditions: Metastatic Cancer, Carcinoma, Adenocarcinoma.
What interventions are being tested in trial NCT05065736?
The interventions under investigation include: 18F-Clofarabine (DRUG).
Who is sponsoring clinical trial NCT05065736?
This trial is sponsored by Roberto Vargas, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05065736 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05065736's enrollment target sits among peer trials
4 109th of 109 higher than 1 of 109 other Metastatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single-Arm
COMPLETED · Early Phase 1
-
Evaluating Disparities in Precision Oncology
RECRUITING
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI